Table 2.
Monoclonal antibodies, their indications, and dosage regimen.
| Monoclonal antibody | Indication | Dose | Frequency | N (%), (n = 348) |
|---|---|---|---|---|
| Evolocumab | Hyperlipidemia | 140 mg | Q2W | 87 (25.0) |
| Once | 48 (13.8) | |||
| Palivizumab | Congenital heart disease (CHD) respiratory syncytial virus (RSV) infection | 15 mg/kg | Q1M | 99 (28.4) |
| Once | 5 (1.4) | |||
| Dupilumab | Eczema, asthma, sinusitis, nasal polyposis | 200 mg, 300 mg | Q2W | 37 (10.6) |
| Q3W | 1 (0.3) | |||
| Denosumab | Osteoporosis | 60 mg | Once | 12 (3.4) |
| Q6M | 18 (5.2) | |||
| Romosozumab | Osteoporosis | 105 mg, 210 mg | Q1M | 20 (5.7) |
| Secukinumab | Psoriasis, rheumatoid arthritis | 300 mg | Q1W | 1 (0.3) |
| Q4W | 11 (3.2) | |||
| Omalizumab | Asthma, urticaria | 300 mg | Q2W | 1 (0.3) |
| Q6M | 3 (0.9) | |||
| Adalimumab | Rheumatoid arthritis psoriasis | 40 mg | Q2W | 2 (0.6) |
| Erenumab | Migraines | 70 mg | Q1M | 1 (0.3) |
| Ustekinumab | Psoriasis | 45 mg | Q3M | 1 (0.3) |
| Mepolizumab | Asthma | 100 mg | Q4W | 1 (0.3) |
Q1W: every 1 week; Q2W: every 2 weeks; Q4W: every 4 weeks; Q1M: every 1 month; Q6M: every 6 months.